59.02USD+4.29%Mkt Cap: —P/E: 15.451d ago
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value3.48B $
Revenue (TTM)13.39M $
Gross Profit-461.80M $
Net Income (TTM)-451.14M $
Revenue/Share0.1410 USD
Last Price59.02 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINCH0334081137
Valuation
P/E (Trailing)15.45
P/E (Forward)—
PEG—
EV/EBITDA-6.79
EV/Revenue260.17
P/S—
P/B2.94
EPS (TTM)3.86
EPS (Forward)—
52W Range
51.8679% of range60.95
52W High60.95 USD
52W Low51.86 USD
Profitability
Gross Margin0.00%
Oper. Margin-1127.55%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-26.10%
ROA-14.20%
Growth
Revenue Growth1041.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-369.58M $
CapEx (TTM)—
FCF Margin-1611.75%
FCF Yield—
Net Debt-1.58B $
Net Debt/EBITDA3.08
Balance Sheet
Debt/Equity44.87
Current Ratio17.85
Quick Ratio17.79
Book Value/Sh18.07 USD
Cash/Share24.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float96.21M
Insiders5.89%
Institutions77.85%
Technical
SMA 5071.57 (-17.5%)
SMA 20058.84 (+0.3%)
Beta1.74
S&P 52W Chg20.80%
Avg Vol (30d)6.67K
Avg Vol (10d)2.55K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—